Bristol Myers drops another CytomX program
12 Mar 2024
Phase 2Financial StatementClinical Trial Failure
Bristol Myers Squibb dropped another CTLA-4 program from its decade-long research collaboration with CytomX after the big pharma reviewed its portfolio.
CytomX announced the change in
its 2023 financial results
on Monday, noting that the companies are still collaborating on multiple preclinical programs, including T cell engagers. It was notified by BMS on March 6 that the anti-CTLA-4, BMS-986288, won’t advance beyond its current trial. That
Phase II study
is investigating the drug as a monotherapy and in combination with nivolumab for patients with advanced solid tumors and is set to wrap up in April, according to clinicaltrials.gov.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
Drugs
Chat with Hiro
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.